EC
ALXO icon

EntryPoint Capital’s ALX Oncology ALXO Stock Holding History

EntryPoint Capital’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-76,415
Closed -$461K – 626
2024
Q2 		$461K Buy
76,415
+73,568
+2,584% +$905K 0.21% 46
2024
Q1 		$31.7K Buy
+2,847
New +$40K 0.03% 936

Other funds holding ALXO

VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EntryPoint Capital's ALXO Position: Q3 2024 in Review

EntryPoint Capital sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 76,415 shares — an estimated $461K sold.

EntryPoint Capital first reported a position in ALXO in Q1 2024 and held it in 2 quarters. The position peaked at $461K in Q2 2024. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

  • EntryPoint Capital reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 76,415 ALX Oncology shares in Q3 2024, an estimated $461K.
  • EntryPoint Capital first reported a position in ALX Oncology in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's ALX Oncology position peaked at $461K in Q2 2024.
  • 92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.